Literature DB >> 20153652

Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors.

Gilda Neves1, Ricardo Menegatti, Camila B Antonio, Luiza R Grazziottin, Renan O Vieira, Stela M K Rates, François Noël, Eliezer J Barreiro, Carlos A M Fraga.   

Abstract

We described herein the design, synthesis, and pharmacological evaluation of N-phenylpiperazine heterocyclic derivatives as multi-target compounds potentially useful for the treatment of schizophrenia. The isosteric replacement of the heterocyclic ring at the biaryl motif generating pyrazole, 1,2,3-triazole, and 2-methylimidazole[1,2-a]pyridine derivatives resulted in 21 analogues with different substitutions at the para-biaryl and para-phenylpiperazine positions. Among the compounds prepared, 4 (LASSBio-579) and 10 (LASSBio-664) exhibited an adequate binding profile and a potential for schizophrenia positive symptoms treatment without cataleptogenic effects. Structural features of this molecular scaffold are discussed regarding binding affinity and selectivity for D(2)-like, 5-HT(1A), and 5-HT(2A) receptors. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20153652     DOI: 10.1016/j.bmc.2010.01.040

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

1.  Classification of 5-HT(1A) receptor agonists and antagonists using GA-SVM method.

Authors:  Xue-lian Zhu; Hai-yan Cai; Zhi-jian Xu; Yong Wang; He-yao Wang; Ao Zhang; Wei-liang Zhu
Journal:  Acta Pharmacol Sin       Date:  2011-10-03       Impact factor: 6.150

2.  Pharmacological characterization of N1-(2-methoxyphenyl)-N4-hexylpiperazine as a multi-target antagonist of α1A/α1D-adrenoceptors and 5-HT1A receptors that blocks prostate contraction and cell growth.

Authors:  Fernanda Chagas-Silva; Jéssica Barbosa Nascimento-Viana; Luiz Antonio S Romeiro; Luana C Barberato; François Noël; Claudia Lucia Martins Silva
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-10       Impact factor: 3.000

3.  A new piperazine derivative: 1-(4-(3,5-di-tert-butyl-4-hydroxybenzyl) piperazin-1-yl)-2-methoxyethan-1-one with antioxidant and central activity.

Authors:  Adriane F Brito; Patrícia C C S Braga; Lorrane K S Moreira; Dayane M Silva; Daiany P B Silva; Germán Sanz; Boniek G Vaz; Flávio S de Carvalho; Luciano M Lião; Rafaela R Silva; François Noël; Hiasmin F S Neri; Paulo C Ghedini; Murilo F de Carvalho; Eric de S Gil; Elson A Costa; Ricardo Menegatti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-12-19       Impact factor: 3.000

4.  An Assessment of the Permeation Enhancer, 1-phenyl-piperazine (PPZ), on Paracellular Flux Across Rat Intestinal Mucosae in Ussing Chambers.

Authors:  V A Bzik; D J Brayden
Journal:  Pharm Res       Date:  2016-07-07       Impact factor: 4.200

5.  Antinociceptive effect and mechanism of supercritical carbon dioxide extract of Aloysia gratissima leaves in mice.

Authors:  Maryelen A Souza; Jaqueline Scapinello; João G G Guzatti; Mikaela Scatolin; Rafael Martello; Monica S Z Schindler; Jean F F Calisto; Bianca Alves; Letícia V Morgan; J Vladimir Oliveira; Jacir Dal Magro; Liz G Müller
Journal:  Biomed J       Date:  2020-07-02       Impact factor: 7.892

6.  Synthesis and evaluation of a series of 2-substituted-5-thiopropylpiperazine (piperidine)-1,3,4-oxadiazoles derivatives as atypical antipsychotics.

Authors:  Yin Chen; Xiangqing Xu; Xin Liu; Minquan Yu; Bi-Feng Liu; Guisen Zhang
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

7.  Synthesis and biological investigations of 3β-aminotropane arylamide derivatives with atypical antipsychotic profile.

Authors:  Jacek Stefanowicz; Tomasz Słowiński; Martyna Z Wróbel; Grzegorz Ślifirski; Maciej Dawidowski; Zdzisława Stefanowicz; Magdalena Jastrzębska-Więsek; Anna Partyka; Anna Wesołowska; Jadwiga Turło
Journal:  Med Chem Res       Date:  2018-06-22       Impact factor: 1.965

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.